Exact Sciences Corp (EXAS) is a publicly traded Healthcare sector company. As of May 21, 2026, EXAS trades at $104.91 with a market cap of $20.03B and a P/E ratio of -95.37. EXAS moved -0.02% today. Year to date, EXAS is +56.63%; over the trailing twelve months it is +136.92%. Its 52-week range spans $38.81 to $104.98. Analyst consensus is buy with an average price target of $103.18. Rallies surfaces EXAS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Abbott Finalizes $23 Billion Exact Sciences Acquisition to Control Cologuard Tests: Abbott has completed its $23 billion acquisition of Exact Sciences, gaining control of the Cologuard colorectal cancer screening test. Exact Sciences’ 7,000 employees—about half based in Madison—and its diagnostic labs will remain under Abbott as it expands into precision oncology.
| Metric | Value |
|---|---|
| Price | $104.91 |
| Market Cap | $20.03B |
| P/E Ratio | -95.37 |
| EPS | $-1.10 |
| Dividend Yield | 0.00% |
| 52-Week High | $104.98 |
| 52-Week Low | $38.81 |
| Volume | 21.56M |
| Avg Volume | 0 |
| Revenue (TTM) | $3.25B |
| Net Income | $-207.95M |
| Gross Margin | 69.69% |
41 analysts cover EXAS: 0 strong buy, 22 buy, 17 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $103.18.